A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies

NCT02244112 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
43
Enrollment
INDUSTRY
Sponsor class

Stopped Why study stopped revised to "A program evaluation identified that the safety profile and pharmacokinetic (PK) characteristics of the formulation used in all oprozomib studies required further optimization and thus enrollment in OPZ009 was halted

Conditions

Interventions

Sponsor

Amgen